Navigation Links
Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
Date:2/5/2009

BEIJING, Feb. 5 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical products developer, manufacturer and distributor in the People's Republic of China, today announced that its contractually controlled subsidiary Beijing Liang Fang Pharmaceutical Co., Ltd. (''Liang Fang'') completed paying RMB180 million (about $26.3 million) in December 2008 for land use rights to property in the Chahaer Industrial Park, located in Inner Mongolia. This was an important step towards achieving the Company's long term growth plans.

Developing a New Facility and Pharmaceutical Park

The land use rights are for 1,000 mu (1mu = 667square meters) of land. Liang Fang plans to build a 50 mu (33,350 square meters) pharmaceutical products production, administration, storage and logistics facility on a 200 mu parcel of land. It plans to sell or rent the additional 800 mu of land to other pharmaceutical companies to create a Pharmaceutical Park of similar companies, a cluster of pharmaceutical companies which it hopes will find mutually beneficial ways of working together.

Liang Fang had its project proposal approved by the local Chayouqian county government before paying Chahaer Industrial Park for the land use rights. The Chayouqian county government has submitted Liang Fang's final project proposal documents to the National Bureau of Land and Resources, which must issue a land use permit before construction may begin on the new facility. Liang Fang expects to receive that permit in March or April of 2009. If the project is not approved and a land use permit is not issued, the full amount that Liang Fang paid for land use rights will be refunded to Liang Fang.

Lotus generated the RMB180 million that it paid for land use rights by speeding up its collection of accounts receivable in 2008.

The cost of developing Lotus' new facility and Pharmaceutical Park will require an estimated additional RMB400 million (about $58.5 million). Plans call for funding the estimated additional RMB400 million through a combination of internally generated cash, low interest local bank loans collateralized by the land, government grants distributed through China's Western Region Development Policy and Technology Sponsorship Policy, the sale or rental of land use rights to the 800 mu of land which will not be used for its new facility or Pharmaceutical Park, and other financing means. Lotus recently submitted its feasibility study for development of its new facility and Pharmaceutical Park to the National Development and Reform Commission as part of its application for a government grant.

''As part of our long term plans for growth, we are pleased to have purchased the land use rights for property on which to develop a new facility and Pharmaceutical Park, and are excited by this opportunity to expand our business in Inner Mongolia,'' said Dr. Zhongyi Liu, the CEO and Chairman of Lotus. ''This important first step puts our plans for expansion during the next five years into action.''

Construction of the new facility is estimated to take three years.

Inner Mongolia Offers Cost Savings

Liang Fang's Inner Mongolia branch, established in December 2008, has a business registration certificate from Inner Mongolia's local government. Lotus' wholesale business for the distribution of drugs is now conducted through Liang Fang's Inner Mongolia branch, which anticipates that it may not have to pay any income taxes for an eight year period, and anticipates on paying income taxes at a reduced rate for the subsequent eight years.

''We expect to realize significant cost savings by expanding into Inner Mongolia. Once our new facility is completed and sales begin, we expect our new Inner Mongolia operations, like our wholesale distribution business, to be free from income taxes for eight years and pay income taxes at a reduced rate for the subsequent eight years. Also, we expect to enjoy a preferential VAT policy in Inner Mongolia, labor is less expensive, and the cost of utilities will be lower there,'' said Dr. Liu.

Developing New Products

In its feasibility study for developing an Inner Mongolia facility, the Company highlights the huge market potential in China for domestically produced intravenous fluids. China consumes about seven billion bottles of intravenous fluids every year, and the top two intravenous fluids producers in China can produce less than 8% of the amount that is needed. The plant protein that is the main ingredient used in producing a blood plasma substitute, one kind of intravenous fluid among the many which the Company plans to produce, is extracted from corn, and the area around the Chahaer Industrial Park is one of the top corn producing areas in China. Lotus plans to produce 20,000 metric tons of medical-grade corn starch as raw material for its blood plasma substitute, and a total of 240 million bottles of blood plasma substitute and other kinds of intravenous fluids a year. In the realm of drug production, this type of production is categorized as agricultural deep processing, and is in compliance with China's agricultural development policies. Byproducts from the processing of corn can be turned into animal feed.

Lotus will apply for production permits from the Chinese government for intravenous fluid products after the new Inner Mongolia facility is built and equipped.

Lotus will keep its research and development, retail drugstore management, clinical trial drug production facilities for Phase I, II and III testing, and production of its four current drugs in its current Beijing facilities even after the Inner Mongolia project is completed. Any new drugs which are approved for production and distribution before the new facility is built will first be produced in Beijing. Production and distribution of new drugs will eventually move to the new Inner Mongolia facility once the new facility is finished.

About the Chahaer Industrial Park

Creation of the Chahaer Industrial Park was approved by the State Council in 2003 as an important means of assisting the under-developed western regions. It consists of 10.41 square kilometers of land located in the county of Chayouqian of Wulanchabu City in Inner Mongolia, around two hours and thirty minutes driving time from Beijing. A number of the Chinese government's preferential tax and operating subsidy policies automatically cover companies located in the park. About one third of the park is currently occupied. Information about Chahaer Industrial Park is available at: http://www.cyqq.gov.cn .

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. controls and operates Liang Fang Pharmaceutical, Ltd. ("Liang Fang") and Enze Jiashi Pharmaceutical, Ltd. ("Enze"), two pharmaceutical companies located in Beijing, China. Together, Liang Fang and Enze ("Lotus East") undertake the development, production, marketing and distribution of pharmaceutical products. Lotus East has some of the most advanced pharmaceutical production equipment in China and its manufacturing facilities meet national Good Manufacturing Practices (GMP). The Company distributes its own portfolio of drugs and pharmaceutical products produced by other manufacturers in the PRC through an extensive national distribution network. Lotus owns ten pharmacies in Beijing through which it directly sells over 5,000 western drugs, Traditional Chinese Medicines (TCM) and medical equipment items.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K filed with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

    For more information, please contact:

    Lotus Pharmaceuticals, Inc.
     Mr. Adam Wasserman, CFO
     Tel:   +1-877-801-0344
     Email: info@LotusEast.com
     Web:  http://www.lotuseast.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
2. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
3. Lotus Pharmaceuticals Raises $5 Million in Private Placement
4. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
5. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
6. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
7. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
8. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
9. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
10. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: